Letrozol Azevedos

Letrozole, the active ingredient in Letrozol Azevedos, is a aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozol Azevedos as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Azevedos is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer. - Hormone receptor‑positive breast cancer (adjuvant): Reduces risk of recurrence after surgery in postmenopausal women. - Hormone receptor‑positive metastatic breast cancer: Delays disease progression in postmenopausal patients with advanced disease. - Estrogen‑dependent breast cancer: Lowers circulating estrogen to inhibit tumor growth in eligible patients.

Letrozol Azevedos may cause a range of adverse reactions.

Common Side Effects: - Hot flashes - Joint or muscle pain - Fatigue - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe bone loss or osteoporosis leading to fractures - Cardiovascular events such as hypertension or thromboembolism - Elevated liver enzymes or hepatic dysfunction - Severe allergic reactions including anaphylaxis - Deep vein thrombosis or pulmonary embolism - Significant cholesterol abnormalities

Before initiating therapy, several safety considerations should be reviewed. - Pregnancy: Contraindicated; teratogenic (Category X). - Bone health: Monitor bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular: Assess risk factors and monitor blood pressure and lipid profile regularly. - Liver function: Use with caution in hepatic impairment; periodic liver enzyme testing recommended. - Drug interactions: Review concomitant medications for CYP2A6 substrates or inhibitors. - Store at ambient temperature: Keep below 25°C in the original packaging, protect from moisture and light.

Letrozol Azevedos can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors (e.g., fluvoxamine): May increase letrozole exposure. - Estrogen‑containing hormone therapy: Opposes therapeutic effect of letrozole. - Tamoxifen: Reduces the efficacy of letrozole when used concurrently.

Moderate Interactions (Monitor Closely): - CYP2A6 inducers (e.g., rifampin): May lower plasma concentrations of letrozole. - Anticoagulants (e.g., warfarin): Potential alteration of INR; monitor coagulation status. - Selective serotonin reuptake inhibitors (e.g., paroxetine): May require symptom monitoring for additive side effects.